Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

van der Heijde, DésiréeDésiréevan der HeijdeCheng-Chung Wei, JamesJamesCheng-Chung WeiDougados, MaximeMaximeDougadosMease, PhilipPhilipMeaseDeodhar, AtulAtulDeodharMaksymowych, Walter PWalter PMaksymowychVan den Bosch, FilipFilipVan den BoschSieper, JoachimJoachimSieperTomita, TetsuyaTetsuyaTomitaLandewé, RobertRobertLandewéZhao, FangyiFangyiZhaoKrishnan, EswarEswarKrishnanAdams, David HDavid HAdamsPangallo, BethBethPangalloCarlier, HildeHildeCarlierSONG-CHOU HSIEH2023-09-192023-09-192018-12-0801406736https://www.scopus.com/record/display.uri?eid=2-s2.0-85055119391&doi=10.1016%2fS0140-6736%2818%2931946-9&origin=inward&txGid=3263143fed2594ab3ebbc36541992ba8https://scholars.lib.ntu.edu.tw/handle/123456789/635443Biological disease-modifying anti-rheumatic drugs (bDMARDs) are recommended for radiographic axial spondyloarthritis, otherwise known as ankylosing spondylitis, when conventional therapies are not effective. We report efficacy and safety data on ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A (IL-17A), in patients with radiographic axial spondyloarthritis who have not previously been treated with bDMARDs.en[SDGs]SDG14Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trialjournal article10.1016/S0140-6736(18)31946-9303609642-s2.0-85055119391https://api.elsevier.com/content/abstract/scopus_id/85055119391